Patients with presbyopia achieved visual acuity improvement with LNZ100 in the phase 3 CLARITY safety and efficacy trials, according to a press release from Lenz Therapeutics.The CLARITY 1 and 2 trials investigated the eye drops LNZ100 (1.75% aceclidin…
Author: Healio ophthalmology
VIDEO: Options other than medications needed for 24/7 IOP control
TAMPA, Fla. — In a presentation from Telling It Like It Is, Analisa Arosemena, MD, discussed the path to achieving 24/7 IOP control for patients with glaucoma and the role that canaloplasty may play.According to Arosemena, ophthalmologists should move …
Qlaris Bio initiates trials for potassium channel modulator therapy in glaucoma patients
Qlaris Bio announced the initiation and dosing of two phase 2 trials aimed at assessing QLS-111, a therapy for lowering intraocular pressure by targeting episcleral venous pressure, or EVP, in patients with glaucoma.The ATP-sensitive potassium channel …
VIDEO: Iridex lasers offer continuous wave, MicroPulse treatment modalities
WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Joan Stauffer, director of marketing and communications for Iridex, discusses new laser systems from the company.The 532 and 577 laser systems are designed for the treatment of r…
VIDEO: ASCRS Foundation previews upcoming events for meeting attendees
In this Healio Video Perspective, Abigail Markward, MBA, executive director of The American Society of Cataract and Refractive Surgery Foundation, provides an overview of events the foundation will be running during the ASCRS 2024 meeting.These events …
Q&A: Discussing benefits, risks of options key to refractive surgery evaluations
Patients with myopia may qualify for several refractive surgery options depending on their age, lifestyle, corneal health and expectations.To help patients feel more comfortable with surgery and increase their satisfaction after the procedure, it is im…
First Canadian patient dosed in cell therapy trial for corneal edema
The first Canadian patient has been dosed in a phase 1/2 trial of a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release.The drug, AURN001 (Aurion Biotech), is a combination cell the…
ViaLase secures $40 million in Series C financing to advance femtosecond laser
ViaLase has secured approximately $40 million in Series C financing to drive the continued development of the company’s femtosecond laser for the treatment of glaucoma, according to a press release.The financing was led by a new investor and supported …
Viatris launches Ryzumvi for mydriasis reversal
Viatris is launching the first commercially available, FDA-approved eyedrop for the reversal of dilation, according to a press release.The FDA approved Ryzumvi (phentolamine ophthalmic solution 0.75%) in September 2023 following positive results of two…
Ophthalmology meeting news: The biggest stories of 2024 so far
The first quarter of 2024 has come to a close, but Healio’s ophthalmology meeting news coverage is just getting started.Catch up on the most popular meeting news stories of the year so far, including the historic launch of a whole eye transplantation r…
VIDEO: Algorithm changes may affect pay-per-click campaign precision, return on investment
In this Healio Video Perspective, Cynthia A. Matossian, MD, FACS, and David Evans, PhD, MBA, discuss recent changes to Google’s algorithm that may impact the precision of pay-per-click advertising campaigns.The algorithm change has broadened the result…
VIDEO: Understand the return on investment of a pay-per-click advertising campaign
In this Healio Video Perspective, Cynthia A. Matossian, MD, FACS, and David Evans, PhD, MBA, explain the role that pay-per-click advertising can play in promoting a practice online.Their discussion includes how to measure the efficacy of a pay-per-clic…
VIDEO: Check for signs of uveitis-glaucoma-hyphema syndrome when repositioning IOLs
TAMPA, Fla. — In a presentation from Telling It Like It Is, María H. Berrocal, MD, FASRS, uses surgical footage to showcase techniques for repositioning an IOL, including in patients with uveitis-glaucoma-hyphema syndrome.“Always suspect UGH when you h…
Aldeyra plans new drug application resubmission for reproxalap
Nearly 5 months after the FDA did not approve reproxalap for dry eye, Aldeyra Therapeutics has announced a plan to resubmit a new drug application for the reactive aldehyde species modulator, according to a press release.The company plans to initiate a…
VIDEO: New Eyeluminaries episode, featuring Wiley A. Chambers, MD, is live on Healio
In this Healio Video Perspective, John A. Hovanesian, MD, FACS, and Jim Mazzo preview the latest episode of the Eyeluminaries podcast.This episode features industry insights from Wiley A. Chambers, MD, as well as a new iteration of the podcast’s annual…
VIDEO: Miebo stops evaporation, keeps tears flowing
WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Douglas Katsev, MD, and Julia Katsev Larson, OD, discuss the use of Miebo for dry eye disease.“Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) is a great addition…
Geographic atrophy treatment Izervay receives permanent J-code
CMS has assigned a permanent J-code for Izervay for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Iveric Bio.The new code for Izervay (avacincaptad pegol intravitreal solution) for …
Opus Genetics completes dosing in first cohort of Leber congenital amaurosis trial
Dosing is complete in the first cohort of the phase 1/2 clinical trial of OPGx-LCA5 for the treatment of Leber congenital amaurosis, according to a press release from Opus Genetics.An adeno-associated virus 8 vector is used to deliver a functional LCA5…
Timolol microdrops appear as effective as conventional drops in lowering IOP
Timolol maleate 0.5% microdrops delivered with the Nanodropper Adaptor met three noninferiority endpoints in lowering IOP compared with conventional timolol drops, according to a study.“We anticipate the Nanodropper system with timolol will revolutioni…
Gene therapy improves vision in patients with retinitis pigmentosa in phase 2b trial
MCO-010 demonstrated positive topline results in vision improvement in patients with permanent and severe vision loss from advanced retinitis pigmentosa, according to a press release from Nanoscope Therapeutics.The mutation-agnostic gene therapy also d…